Exenatide, a synthetic version of exendin-4, a GLP-1 receptor agonist, is widely used to treat diabetes and obesity and has the potential to be repurposed for the treatment of increased ICP (Fig
Rehefa mandeha ny fotoana, io fanangonana tavy io dia miteraka areti-maso ary mety hivoatra amin'ny steatohepatitis, fibrosis, cirrhose, ary amin'ny farany ny tsy fahombiazan'ny atiny na ny homamiadana
doi:10.1097/med.0000000000000095 193
Patients working with their physicians to document failed weight loss attempts and cardiovascular risk factors improve their chances of obtaining coverage
Bethesda, Maryland, National Heart, Lung and Blood Institute, 72 pp (NIH Publication No
Low-dose activation of glucagon receptors can increase energy expenditure and promote the burning of stored fat